Member Info for Bella6532

AVCT...I will - not up yet...happy to be corrected...

WE DO NOT WANT TO BE TAKEN OVER NOW...We'd be luck if we got £1.50 a share...which is just over double where we are now.

NO, value has to be added through deals...we are developing a PLATFORM of products...the BASIC PLATFORM is what needs to be established through in clinic trials...then it's a case of 'certainly sir and what would you like to go into your PreCision product?'...'We'll do the initial lab work (for a nice up fron payment) and then it's yours to run with and once you get it to market we'll happily bank the Royalty cheques'....'Perfect, sign here'...'Next'

Oh and of course I forgot to mention Approvals...much easier to get approval for the likes of our combo than drugs administered separately in combo...

Oops! sorry should have read.....'far more effective and safer than the individual parts administered on their own...'

oh dear...what on earth did you guys expect from today...????

as cc said...trials take time...getting new products developed takes time...lots of time...

now let's unpick what was said....basically the new combo is first and best in class to date...it makes adc's look like a very expensive waste of time...they are very expensive to produce, they can't be easily controlled, they are large cumberson molecules which have difficulty getting to where they need to and they have some pretty bad side effects....derrrrr!!! those big pharmas have really spent a lot of money on a pile of ****e!!! which i'm sure most don't realise and most will continue to try and make a go of them...

now our combo is very itsy bitsy and nimble...it charges straight to the nasty tumour site, dumps it payload (and we can programme its rate of release) and because it's such a nifty little sucker it has a x4-5 cancer cell killing rate...all importantly the chemo drug and resistance drug are released in the same place at the same time for maximum effect and some.

other very important points:

1. they are going for drugs that are not currently on the market!!!!...so for whatever reason they are on the shelf unable to be used in their current format.

2. these new combos will be easy and cheap to make and potentially far more effect and safe than the indivisual parts on their own.

3. this combo in clinic approx 1 year from now.

4. pharma needs a little more data...it's on it's way.

5. a platform needs two products in clinic...the next enters clinic q1 2026.

i can wait....can you????

Some nice trades today...

🤣🤣🤣

Haha...looks like they need PreCision to solve their PDC issues...

https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-025-03277-2

More DATA

A DEAL

Some more DOSH...

And go wake the markets up a big II...if the likes of HR backs up a Licence deal with a massive chunk of finance deal too the markets will choke on their champers and want in...in... In...so what about a hybrid deal...

If Bryant isn't working on this sort of deal...what's he on board for...

BV that's very much the problem with most PI share investments...they buy in late and hold too long only to sed their gains disappear..hence a lot of the moaning you see on BBs. Trading should not be classed as a dirty word..it's what we all do when we buy and sell. Of course you don't have to sell...I wasn't suggesting that...just there appeared to be a pattern and if the pattern continued this should be a good uptick week and 90 appeared to be the new high it might reach...

Episode 50

https://www.optimumcomms.com/optimumtv/#episode50

Bella...'IF the pattern continues then we should hit 90 by end next week. Now what bit of news will be dropped to help it along???'

Hey BV...we got the news yesterday...

80 by end of week = average +5% daily

90 by end of week = average + 8% daily

I wonder what today will bring...yesterday morning would I would have put money on 90...perhaps it's be closer to your 80 now...

'The pre|CISION® platform has been validated by compelling clinical data with faridoxorubicin (AVA6000, FAP-Dox)'

The PreCision PLATFORM.....has been validated.....

Markets use key word alerts...you can too if you use certain broker sites.

BV..hence Avacta talking about keeping the IP...

DAH DAH...

'The pre|CISION® platform has four key advantages over traditional ADC delivery, including tumor-specific payload release that avoids the toxicities associated with nonspecific release, small molecule manufacturing, better tumor penetration and bystander effect, along with a large addressable market of 90% of solid tumors.'

WICKED...4-5 FOLD GREAT CELL KILLING...

'FAP-Exd/PARPi and FAP-Exd/ATRi compounds demonstrated 4-5 fold greater FAP-dependent tumor cell killing compared to exatecan alone, directly addressing the known DDR-mediated resistance pathway to topoisomerase I inhibitors.'

WOW...

'Modifications to the self-immolative linkers enabled tunable payload delivery kinetics, providing flexibility to optimize therapeutic profiles for different payload combinations. Strategic modifications of linker and capping group structures enabled optimization of compound activity.'

Sorry for some reason capitals not working...

side effects...side effects...side effects...

combo drugs aren't always give to kill the tumour they are to help with the side effects ...have any of you come home after each chemo sessions with a bottle attached containing a ****tail of chemicals...nah thought not...

chemo isn't just about combo drugs being administered at the same time...it's about many drugs being administered.

now if precision takes the warehead (chemo) directly to the tumour and it can be administered at x4 normal doe every two weeks not three weeks with very few serious side effects, then all i am saying is it may reduce the '****tail' of other drugs administered be it at the same time or afterwards.

i can see the need for a resistance drug. from what i also see is that due to the high toxicity of some of these chemo drugs they could not be administered in high doses and therefore combos have been developed to help with 1. resistance and 2. efficacy.

precision of course is about delivering directly into the tumour and once there it's the drugs it delivers which have to do their job. if dox isn't efficient that's the problem with dox not precision. if the resistance drug isn't efficient that's the problem with that drug. however, precision is enabling much higher doses over potentially a much shorter timescale which should make the drugs it takes to the tumour more effective...fingers crossed and all that...

now let's see what 1b data gives us...and more importantly what phase 2 data t all this good stuff.

personally, i don;t think we need to get too wrapped up in the science...the concept is far simpler than that...it's precise and it works...(precision not the drugs)...